Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Alessandra Sperotto, MD
CONTACT
Gian Luca De Salvo, MD
CONTACT
Lead
Istituto Oncologico Veneto IRCCS
With
A total of 14 patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) will be enrolled. This sample size is intended to provide a sufficient cohort to evaluate the feasibility, safety, and preliminary efficacy of the combined therapy of CIK\_D332, Tafasitamab, and Lenalidomide, while allowing for early assessment of the therapeutic approach in the specified patient population. The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK\_D332, administered as follows: * Tafasitamab: Administered at a dose of 12 mg/kg IV. * Cycle 1 (28-day): Days 1, 4, 8, 15, and 22. * Cycles 2-3: Days 1, 8, 15, and 22. * Cycles 4-5: Days 1 and 15. * Lenalidomide: Administered at 25 mg orally on days 1-21 of each cycle (up to 5 cycles). Dose adjustments are applied according to the label for renal clearance and toxicity. * CIK\_D332 Cells: Administered in cycles 2-5 (up to 8 doses total). * Administration: Infused after Tafasitamab on days 1 and 15. In patient with previous infusion-related reactions requiring premedication with glucocorticosteroids also in cycles 2-5, CIK\_D332 will be infused the following day * Dosage: 3-5 x 106 cells/kg (total 225-300 x 106 cells). * Note: The number of doses (2-8) depends on CIK\_D332 cell amount produced. Patients receiving fewer than 2 doses will not be evaluable for secondary objectives. * Maintenance: Following a clinical response, patients may continue treatment with Tafasitamab and Lenalidomide, without CIK\_D332, until disease progression as per the label.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
